We are live on ! Find out more
JSPRW icon

Japer Therapeutics Warrants
JSPRW

8 hedge funds and large institutions have $1.09M invested in Japer Therapeutics Warrants in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

185% more capital invested

Capital invested by funds: $383K → $1.09M (+$709K)

33% more funds holding

Funds holding: 68 (+2)

20.51% less ownership

Funds ownership: 20.51%0% (-21%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
8
Holders Change
+2
Holders Change %
+33.33%
% of All Funds
0.1%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
Reduced
1
Closed
1
Calls
Puts
Net Calls
Net Calls Change

JSPRW Hedge Fund Activity: Q3 2025 in Review

8 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Japer Therapeutics Warrants (JSPRW) for Q3 2025, worth a combined $1.09M — up 185% from $383K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new JSPRW positions and 1 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Boothbay Fund Management, opening a new position worth an estimated $30.4K. The largest seller was Zazove Associates, exiting entirely with an estimated $6.21K sold.

  • 8 institutional investors held Japer Therapeutics Warrants (JSPRW) as of Q3 2025, up from 6 in Q2 2025.
  • Funds reported $1.09M of Japer Therapeutics Warrants stock for Q3 2025, up 185% quarter-over-quarter.
  • 3 funds opened new Japer Therapeutics Warrants positions in Q3 2025 and 1 closed out, a net change of +2 holders.
  • The largest Japer Therapeutics Warrants buyer in Q3 2025 was Boothbay Fund Management, an estimated $30.4K added.
  • The largest Japer Therapeutics Warrants seller in Q3 2025 was Zazove Associates, an estimated $6.21K sold.

Based on aggregated 13F filings for Q3 2025.